Compare Revvity Inc (RVTY) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs VF Corp — how do they compare? Revvity Inc trades at $117.6 (market cap $12.91B), while VF Corp trades at $14.63 (market cap $5.81B). The key difference: Revvity Inc is far larger — about 2.2× VF Corp's market cap, and VF Corp pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| RVTY | VFC | |
|---|---|---|
Market Cap | $12.91B | $5.81B |
Sector | Technology | Consumer Cyclical |
52-Week High | $117.75 | $21.55 |
52-Week Low | $82.26 | $12.21 |
Enterprise Value | $15.23B | $10.09B |
Dividend Yield | 0.24% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
VFC stock trades at $14.69, down 1.41% on the day, reflecting ongoing pressure from recent earnings misses and weak Vans brand performance. Technical indicators are bearish, with the price near key support at $14.00. Fundamentally, revenue has declined from $11.8B in 2022 to $9.5B in 2025, with net losses in 2024 and 2025, though 2026 projects a return to profitability. The company is focused on deleveraging, with debt-to-asset ratio improving to 42.42% in 2025.
The outlook remains challenging due to brand-specific headwinds and macro pressures, but cost controls and a raised fiscal 2027 revenue outlook offer some optimism. Risks include persistent Vans weakness and consumer sentiment, while the consensus price target of $17.44 suggests modest upside if turnaround efforts gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
